Associated Papers
Transcriptomic landscape of CD8+ and CD4 + T-LGL leukemia revealed the distinct impact of STAT3 and STAT5B activating mutations.
Calabretto G et al.
Leukemia, 2025
40721648 (PubMed )
Supplement: 41375_2025_2708_MOESM6_ESM.xlsx › Suppl_table_5
The structural influence of the oncogenic driver mutation N642H in the STAT5B SH2 domain.
Haas-Neill L et al.
Protein Science : a Publication of the Protein Society, 2025
STAT5B mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophilia.
Yin CC et al.
Haematologica, 2024
JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL.
Wahnschaffe L et al.
Cancers, 2019
31766351 (PubMed )
Supplement: cancers-11-01833-s001.zip › Supplementary_Table_3.xlsx › Tabelle1
Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.
Storr HL et al.
Endocrine Reviews, 2019
The Genetic Basis of Hepatosplenic T-cell Lymphoma.
McKinney M et al.
Cancer Discovery, 2017
Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience.
Marks LJ et al.
Frontiers in Pediatrics, 2017
Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.
Oberg JA et al.
Genome Medicine, 2016
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.
Küçük C et al.
Nature Communications, 2015
The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse.
Bandapalli OR et al.
Haematologica, 2014
Select a paper to view details